CIK 0001842295
- Non-accelerated filer
- Emerging growth company
Maze Therapeutics, Inc.
Sign in to watch- Ticker
- MAZE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 650-850-5070
- Business address
- 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
- 4 Planned sale Chief Executive Officer sold 34,501 shares at an average $26.73 ($922,315)
- 4 Planned sale CSBO sold 7,500 shares at an average $27.34 ($205,031)
- 4 Planned sale President, R&D & CMO sold 14,609 shares at an average $29.90 ($436,864)
- 4 Planned sale Chief Executive Officer sold 34,501 shares at an average $29.98 ($1,034,253)
- 4 Planned sale CSBO sold 7,500 shares at $28.02 ($210,150)
- 4 Planned sale Chief Executive Officer sold 27,858 shares at an average $26.04 ($725,495)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Planned sale Chief Executive Officer sold 6,643 shares at an average $26.20 ($174,048)
- 4 Planned sale President, R&D & CMO sold 14,853 shares at an average $25.66 ($381,112)
- 4 Planned sale CSBO sold 7,500 shares at $26.34 ($197,554)
- 4 Planned sale Chief Executive Officer sold 32,564 shares at an average $26.01 ($847,048)
- 4 Planned sale Chief Executive Officer sold 1,938 shares at $26.00 ($50,388)
- 4 Planned sale President, R&D & CMO sold 15,000 shares at $26.22 ($393,354)
- 4 Exercise or conversion CSBO acquired 14,305 shares (option exercise)
- 4 Gift Director gave 7,422 shares (gift)
Page 2 of 6 · 108 filings